Systimmune

SystImmune, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative bi-specific and multi-specific antibodies, as well as antibody-drug conjugates (ADCs) for cancer treatment. Based in Redmond, WA, with operations in Princeton, NJ, SystImmune is part of the Biokin Pharmaceutical Co., Ltd. group and has a strong presence in both the U.S. and China, facilitating efficient clinical development. The company's mission is to create biologics that target tumors and activate the immune system to improve anti-tumor responses. SystImmune has a diverse team of R&D scientists and clinical experts working on an ambitious pipeline, which includes multiple assets in clinical trials for various cancer indications. One of its key products, izalontamab brengitecan (iza-bren), is a bispecific ADC that targets EGFR and HER3 in epithelial cancers and has received U.S. FDA breakthrough therapy designation for certain lung cancer treatments. SystImmune collaborates with Bristol Myers Squibb for the global development of iza-bren and partners with OrbiMed for further commercialization efforts.